Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin 12-activated lymphocytes influence tumor genetic programs.

F Cavallo1, E Quaglino, L Cifaldi

  • 1Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.

Cancer Research
|April 20, 2001
PubMed
Summary

Activated T-lymphocytes (LYs) modulate tumor genetic programs. Interleukin-12 (IL-12) enhances this effect, with interferon-gamma (IFN-gamma) playing a key role in inhibiting tumor growth and angiogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineered natural extracellular matrix platform for modelling skin diseases and identifying therapeutic targets.

Journal of advanced research·2026
Same author

WEARnCARE, a decision support system to enhance monitoring of motor performance in Parkinson's disease patient's journey<sup></sup>.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Antimicrobial efficacy of an experimental UV-C robot in controlled conditions and in a real hospital scenario.

The Journal of hospital infection·2024
Same author

Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Magnetometer-free Kalman filter for motor-based assessment of prodromal Parkinson's disease.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2022
Same author

Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • T-lymphocytes (LYs) are crucial immune cells involved in regulating cellular responses.
  • Interferon-gamma (IFN-gamma) is a cytokine with known immunomodulatory and anti-tumor properties.
  • Understanding how T-lymphocytes influence tumor cell genetics is vital for developing novel cancer therapies.

Purpose of the Study:

  • To investigate the capacity of activated T-lymphocytes, with and without Interleukin-12 (IL-12) stimulation, to alter the gene expression profiles of tumor cells.
  • To elucidate the specific roles of IFN-gamma and other secreted factors in mediating these T-lymphocyte-induced genetic modulations in tumors.
  • To assess the implications of these genetic changes for tumor behavior and potential anti-tumor activity.

Main Methods:

Related Experiment Videos

  • Activation of T-lymphocytes from normal and IFN-gamma knockout mice using anti-CD3 and anti-CD28 antibodies.
  • Co-culture of activated T-lymphocytes with tumor cell lines using transwell systems, with and without IL-12.
  • Analysis of gene expression using cDNA arrays, reverse transcription-PCR, and protein expression analysis.

Main Results:

  • Factors other than IFN-gamma modulated LPS, transcription termination factor 1, transforming growth factor, and fibroblast growth factor genes.
  • High IFN-gamma levels from IL-12-activated LYs up-regulated STAT1, IRF-1, LMP2, LMP7, monokine induced by IFN-gamma, monocyte chemoattractant protein 1, and angiopoietin 2, while down-regulating vascular endothelial growth factor.
  • Specific genes like PA28, IFN-inducible protein 10, inducible NO synthetase, and macrophage-inhibitory protein 2 were modulated by IL-12-activated LYs independently of IFN-gamma.

Conclusions:

  • IL-12-activated T-lymphocytes significantly alter tumor cell gene expression, including the down-regulation of vascular endothelial growth factor and up-regulation of pro-angiogenic factors.
  • These modulations, particularly the interplay between vascular endothelial growth factor and other factors, align with the anti-angiogenic effects observed in IL-12 mediated anti-tumor activity.
  • T-lymphocytes actively modify tumor behavior, contributing to their own inhibition through genetic reprogramming of the tumor microenvironment.